◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Selegiline

Well Researched

Three different drugs in one molecule depending on dose: low oral (1-2.5 mg) is a clean, daily-safe MAO-B preservation tool with…

Aliases (6)
Eldepryl · Zelapar · Emsam · L-deprenyl · Deprenyl · (-)-deprenyl
TYPICAL DOSE
Dose: 1-2.5 mg/day oral, AM only
Daily
ROUTE
Oral (tablet)
Oral
CYCLE
Daily indefinite at low oral
As prescribed
STORAGE
Room temp; original container
Room temp

Overview

What is Selegiline?

Selegiline (L-deprenyl) is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor used clinically for Parkinson's disease and depression (transdermal Emsam). At low oral doses it is also used as a nootropic and longevity-adjacent agent.

Key Benefits

Slows dopamine breakdown in the brain (motor and motivation benefits in Parkinson's), provides mild neuroprotection and antioxidant effects, and at low doses may support mood, motivation, libido, and cognitive performance with minimal stimulation.

Mechanism of Action

Irreversibly inhibits MAO-B, the enzyme that primarily degrades dopamine and phenethylamine in the CNS. This raises synaptic dopamine and PEA, while metabolites (l-amphetamine, l-methamphetamine) contribute mild catecholamine-releasing activity. Selegiline also upregulates antioxidant defenses (SOD/catalase) and has anti-apoptotic effects.

▸Brand options5 known
EldeprylZelaparEmsamL-deprenylDeprenyl

StatusRx-only US (off-label for nootropic; on-label for Parkinson's adjunct + Emsam for MDD); not scheduled / not WADA-banned

Research Indications

Most Effective

What MAO-B does (and what blocking it accomplishes)

Monoamine oxidase B (MAO-B) is an enzyme found mostly in glial cells and serotonergic neurons that breaks down dopamine, phenylethylamine…

Effective

Selectivity is dose-dependent — the critical point

- ≤5 mg/day oral: ~90%+ selective for MAO-B. PEA-pressor protection holds. No tyramine restriction. - 5-10 mg/day oral: Selectivity start…

Effective

TAAR1 / catecholaminergic activity enhancer (CAE) — the secondary mechanism

Beyond MAO-B inhibition, selegiline is a weak agonist at trace amine-associated receptor 1 (TAAR1). Knoll proposed and later research sup…

Investigational

Metabolism — the methamphetamine question

Selegiline is metabolized by CYP2B6 (primary) + CYP2C19 + CYP3A4 (minor) into: 1. N-desmethylselegiline (DMS) — bioactive, weak MAO-B inh…

Investigational

Why "no receptor downregulation" is technically correct

the user's external source claim — "selegiline doesn't downregulate receptors" — is mechanistically defensible and worth understanding pl…

Peptide Interactions

modafinil:
Synergistic

Different mechanisms (DA-tone preservation via MAO-B vs DA reuptake inhibition + histamine + orexin). Stack is widely reported clean in the nootropic communi…

bromantane:
Synergistic

Cleanly orthogonal — bromantane upregulates DA synthesis at the TH/AAAD level + raises brain GSH; selegiline preserves what's already there. No mechanism ove…

l-tyrosine:
Synergistic

PRN under cognitive stress. Tyrosine provides substrate, selegiline preserves the resulting DA. Synergistic within a stress-response window.

ALCAR:
Synergistic

Mitochondrial support for DA neurons + selegiline's enzymatic preservation = compounding neuroprotection mechanisms. Mild synergy.

astaxanthin / DHA / NAC:
Synergistic

Antioxidant/membrane support for the DA neurons selegiline is preserving. Generally additive.

bpap / ppap:
Synergistic

These are next-gen TAAR1-selective enhancers without MAO inhibition. THEORETICALLY synergistic with selegiline at low dose (different mechanisms) but the rat…

bupropion (Wellbutrin):
Avoid

Increases dopaminergic activity (NDRI). Combined with MAO-B inhibitor not formally contraindicated at low selegiline dose, but introduces risk of hypertensio…

SSRIs / SNRIs:
Avoid

Serotonin syndrome risk. At low-oral selegiline (1-2.5 mg) the risk is lower than at higher tiers — there are studies (PMC6019085) showing 4500+ PD patients …

MDMA, methamphetamine, cocaine, MAOIs (other), amphetamine high-dose:
Avoid

Catastrophic combinations.

other MAO-B or MAO-A inhibitors
Avoid

(rasagiline, phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue): redundant + dangerous.

St. John's Wort / 5-HTP / L-tryptophan in high dose:
Avoid

serotonin syndrome risk at higher selegiline tiers. Note: the canonical stack plan includes L-tryptophan 1g pre-bed as a sleep adjunct. At 1-2.5 mg oral sele…

adderall / vyvanse / dexedrine:
Avoid

at low oral selegiline risk is moderated; at any patch tier contraindicated.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

!

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

  • Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  • Week 1
    Steady-state reached for most daily-dosed pharma.
  • Week 2-4
    Therapeutic effect established; titration window if needed.
  • Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety 12

Side Effects

  1. 1Insomnia if dosed PM (avoid by AM-only dosing)
  2. 2Headache (usually transient, first 1-2 weeks)
  3. 3Dry mouth
  4. 4Nausea / GI upset (usually transient, oral > patch)
  5. 5Patch-site skin irritation (Emsam-specific, 15-25%)
  6. 6Orthostatic hypotension — can drop standing BP, especially first 2-4 weeks. Concrete risk for users in this archetype if he stands up fast post-training when already dehydrated/depleted. Monitor.
  7. 7Dizziness / lightheadedness
  8. 8Vivid dreams / sleep disturbance even when AM-dosed
  9. 9Mild anxiety / agitation (usually dose-related, more common >5 mg)
  10. 10Dyskinesia in PD patients (not relevant for users in this archetype-archetype)
  11. 11Mild blood pressure elevation at high tiers
  12. 12Urinary retention (rare at low oral tier, more at high)

When to Stop

  • Hypertensive crisis from tyramine ingestion (HIGH-DOSE TIERS ONLY — 9-12 mg patch or oral >10 mg). Symptoms: severe occipital headache, sweating, palpitations, nausea, BP spike to dangerous range. Real ER event. NOT a concern at 1-2.5 mg oral or 6 mg patch.
  • Serotonin syndrome from co-administration with serotonergic drugs (see Drug Interactions). Symptoms: agitation, hyperthermia, clonus, autonomic instability, tremor, diaphoresis. Can be fatal.
  • Hypomania/mania induction in bipolar-spectrum users (rare, screen family history)
  • Suicidal ideation — black-box warning on Emsam (class effect for antidepressants in <25yo). the user IS in the at-risk age window. Worth flagging though baseline mood is reportedly fine.
  • Hepatotoxicity — very rare, monitor liver enzymes if symptomatic
  • First 2-4 weeks: orthostatic hypotension, sleep disturbance
  • First 6-8 weeks (if starting in someone <25): suicidality risk per black-box (negligible if a user in this archetype has stable mood baseline, but worth being aware of)
  • Post-discontinuation: ~2 week MAO-B regeneration period during which interactions still apply

References

Selegiline (StatPearls, NIH)

ncbi.nlm.nih.gov

comprehensive clinical reference

View Study

Pharmacology of selegiline (Wikipedia)

en.wikipedia.org

mechanism + metabolism + bioavailability comparison

View Study

Selegiline (Wikipedia)

en.wikipedia.org

overview + history + Knoll context

View Study

Emsam selegiline transdermal system FDA label (2015)

accessdata.fda.gov · 2015

official prescribing info, tyramine guidance

View Study

The Selegiline Transdermal System (Emsam) (PMC2730099)

pmc.ncbi.nlm.nih.gov

tyramine bypass mechanism review

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Selegiline
PPAP
SKIP-FOR-NOW
Catecholaminergic activity enhancer (CAE) — first-in-class, deprenyl-derived; also catecholamine reuptake inhibitor (per 2025 revision)
HIGH
Bupropion
OPTIONAL-ADD
NDRI (norepinephrine + dopamine reuptake inhibitor) + nicotinic α4β2 antagonist (atypical antidepressant)
MEDIUM
L-Tyrosine
OPTIONAL-ADD
Conditionally-essential aromatic amino acid; catecholamine precursor (DA, NE, EPI); also thyroid hormone (T3/T4) and melanin precursor
HIGH
9-Methyl-β-carboline
WATCH-LIST
β-carboline alkaloid (tricyclic pyridoindole) — multimodal dopaminergic neurorestorative + dual MAO-A/B inhibitor + neurotrophic-factor inducer
LOW
Enclomiphene Citrate
SKIP-FOR-NOW
Selective Estrogen Receptor Modulator (SERM) — trans-isomer of clomiphene citrate
MEDIUM
Lisuride
SKIP-FOR-NOW
Ergoline / ergolide; non-selective dopamine receptor agonist (D1/D2/D3/D4/D5) with mixed serotonergic activity (5-HT1A/1B/1D full agonist; 5-HT2A/2C partial agonist; 5-HT2B silent antagonist); H1 partial agonist; α-adrenergic silent antagonist
HIGH
Sulbutiamine
OPTIONAL-ADD
Lipophilic thiamine (vitamin B1) disulfide derivative — antiasthenic / mild dopaminergic
MEDIUM
Vyvanse
SKIP-FOR-NOW
Amphetamine prodrug — long-acting d-amphetamine delivered via L-lysine peptide bond, cleaved by RBC aminopeptidase
MEDIUM

More in Pharmaceutical · Oral

94 compounds in bucket
3-n-Butylphthalide (NBP)
OPTIONAL-ADD
Plant-derived multi-target neuroprotectant (phthalide; originally isolated from celery seed Apium graveolens); approved Chinese pharmaceutical for acute ischemic stroke
LOW
5-Amino-1MQ
WATCH-LIST
NNMT inhibitor (nicotinamide N-methyltransferase inhibitor) — small-molecule oral; methylation/NAD-sparing metabolic modulator
LOW
9-Methyl-β-carboline
WATCH-LIST
β-carboline alkaloid (tricyclic pyridoindole) — multimodal dopaminergic neurorestorative + dual MAO-A/B inhibitor + neurotrophic-factor inducer
LOW
ACD-856
WATCH-LIST
Pan-Trk receptor positive allosteric modulator (Trk-PAM) — small-molecule triazinetrione
HIGH
Adderall
SKIP-FOR-NOW
Amphetamine — substituted phenethylamine releasing agent (SNDRA)
MEDIUM
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH